Sabine Linn
Sabine Linn is a breast oncologist testing DNA-damaging chemotherapy in BRCA-like breast cancer.
Sabine Linn leads breast cancer trials at NKI including studies of high-dose alkylating chemotherapy in BRCA1-like tumours and neoadjuvant immunotherapy.
Pages like this
not linked directly; found by shared links- PersonLeif W. Ellisen
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- IdeaA bone drug to prevent breast cancer in BRCA1 carriers
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- InstitutionUniversity of Malaya Medical Centre
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PairingPlatinum chemotherapy in HRD tumours
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD).
- CollectionOvarian Cancer Research Alliance (OCRA)
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD).
- PersonLori J. Pierce
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).